Updated: March 2013
The PI3K-AKT-mTOR pathway is a vital signal transduction cascade associated with many essential cellular activities, including growth and survival. Genetic alterations that disrupt this pathway have been implicated in a wide variety of human tumors. Targeting the three components of this pathway, either separately or in combination, has emerged as a key strategy for cancer treatment.
This report provides intelligence about PI3K-Akt-mTOR signaling cascade modulators. It includes information about new developments in the active Pre-clinical and Clinical pipeline of these modulators (as of March 2013), specifically for the treatment of cancer.
Research validating the therapeutic potential of targeting the PI3K/Akt/mTOR pathway for the cancer treatment, has led to a deluge of kinase inhibitors targeting significant knots of this pathway including phosphatidylinositol-3-kinase (PI3K), serine-threonine protein kinase Akt ((Akt or PKB) and mammalian target of rapamycin (mTOR]. These include both isoform specific as well as isoform non specific inhibitors. Investigational studies with these inhibitors are in various phases of Clinical trials after having proven preclinical safety and effectiveness.
The report presents a compilation of active projects in Pre-clinical and Clinical pipeline development of PI3K-AKT-mTOR inhibitors in Oncology. In addition, the report also lists company specific R&D pipelines of PI3K-AKT-mTOR inhibitors.
Table of Contents
About the Author 4
Pan PI3K inhibitors 5
PI3K Isoform Specific Inhibitors 11
mTOR Inhibitors 20
Akt Inhibitors 48
PI3K/mTOR Dual Inhibitors 56
mTOR and Akt Inhibitor 66
Figure 1: Target-Based PI3K-Akt-mTOR Inhibitors 69
Figure 2: PI3K-Akt-mTOR Inhibitors Vs. Licensee 70
Appendix 2: PI3K-Akt-mTOR Inhibitors R&D pipeline 73
About Parthys Competitive Analysis 74
About Parthys Reverse Informatics 74
Contact Us 74